Interleukin 10 responses are associated with sustained CD4 T-Cell counts in treated HIV infection

Journal of Infectious Diseases

Volumn 206, Issue 5, 2012, Pages 780-789

  Villacres, Maria C ^a,b   Kono, Naoko ^b   MacK, Wendy J ^b   Nowicki, Marek J ^a   Anastos, Kathryn ^e   Augenbraun, Michael ^f   Liu, Chenglong ^g   Landay, Alan ^h   Greenblatt, Ruth M ^c   Gange, Stephen J ⁱ   Levine, Alexandra M ^d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f SUNY DOWNSTATE MEDICAL CENTER   (United States)

^g GEORGETOWN UNIVERSITY   (United States)

^h RUSH UNIVERSITY   (United States)

ⁱ JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; FOLLOW UP; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MIXED INFECTION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; INFLAMMATION; INTERLEUKIN-10; LINEAR MODELS; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; TOLL-LIKE RECEPTOR 3; TOLL-LIKE RECEPTOR 4;

EID: 84864959547     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis380     Document Type: Article

References (50)

1. Deeks SG. HIV infection, inflammation, immunosenescence and aging. Annu Rev Med 2011; 62:141-55.
2. The Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372:293-9.
3. Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the risk of death after HIV seroconversion compared the mortality in the general population. JAMA 2008; 300:51-9. (Pubitemid 351920404)
4. Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007; 146:87-95. (Pubitemid 351640011)
5. Losina E, Schackman BR, Sadownik SN, et al. Racial and sex disparities in life expectancy losses among HIV-infected persons in the United States: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis 2009; 49:1570-8.
6. Baker JV, Peng G, Rapkin J, et al. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 2008; 22:841-8. (Pubitemid 351563833)
7. Ho JE, Deeks SG, Hecht FM, et al. Initiation of antiretroviral therapy at higher nadir CD4+ T-cell counts is associated with reduced arterial stiffness in HIV-infected individuals. AIDS 2010; 24:1897-905.
8. Marin B, Thiébaut R, Bucher HC, et al. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS 2009; 23:1743-53.
9. Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virusinfected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187:1534-43. (Pubitemid 36578959)
10. Kinter AL, Poli G, Fox L, Hardy E, Fauci AS. HIV replication in IL-2-stimulated peripheral blood mononuclear cells is driven in an autocrine/paracrine manner by endogenous cytokines. J Immunol 1995; 154:2448-59.
11. Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179:859-70. (Pubitemid 29159331)
12. Sodora DL, Silvestri G. Immune activation and AIDS pathogenesis. AIDS 2008; 22:439-46. (Pubitemid 351317285)
13. Anastos K, Shi Q, French AL, et al. Total lymphocyte count, hemoglobin, and delayed-type hypersensitivity as predictors of death and AIDS illness in HIV-1-infected women receiving highly active antiretroviral therapy. JAIDS 2004; 35:383-92. (Pubitemid 38332799)
14. Chu H, Gange SJ, Yamashita TE, et al. Individual variation in CD4 cell count trajectory among human immunodeficiency virus-infected men and women on long-term highly active antiretroviral therapy: an application using a Bayesian random change-point model. Am J Epidemiol 2005; 162:787-97. (Pubitemid 41437766)
15. French AL, Gawel SH, Hershow R, et al. Trends in mortality and causes of death among women with HIV in the United States: a 10-year study. J Acquir Immune Defic Syndr 2009; 51:399-406.
16. Chu H, Gange SJ, Li X, et al. The effect of HAART on HIV RNA trajectory among treatment-naïve men and women: a segmental Bernoulli/lognormal random effects model with left censoring. Epidemiology 2010; 21(Suppl 4):S25-34.
17. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cells. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989; 170:2081-95.
18. Fiorentino DF, Zlotnik A, Vieira P, et al. IL-10 acts on the antigenpresenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991; 146:3444-51.
19. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19:683-765. (Pubitemid 32368050)
20. Taga K, Cherney B, Tosato G. IL-10 inhibits apoptotic cell death in human T cells starved of IL-2. Int Immunol 1993; 5:1599-608. (Pubitemid 24008920)
21. Levy Y, Brouet JC. Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. J Clin Invest 1994; 93:424-8. (Pubitemid 24030864)
22. Taga K, Chretien J, Cherney B, Diaz L, Brown M, Tosato G. Interleukin-10 inhibits apoptotic cell death in infectious mononucleosis T cells. J Clin Invest 1994; 94:251-60. (Pubitemid 24218099)
23. Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy-review of a new approach. Pharmacol Rev 2003; 55:241-69.
24. Liew FY, Xu D, Brint EK, O'Neill LA. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 2005; 5:446-58. (Pubitemid 40835033)
25. Schroder M, Bowie AG. TLR3 in antiviral immunity: key player or bystander? Trends Immunol 2005; 26:462-8. (Pubitemid 41139255)
26. Finberg RW, Wang JP, Kurt-Jones EA. Toll like receptors and viruses. Rev Med Virol 2007; 17:35-43. (Pubitemid 46114123)
27. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-71. (Pubitemid 44924494)
28. Blankson JN, Persaud D, Siliciano RF. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 2002; 53:557-93. (Pubitemid 34177896)
29. Villacres MC, Du W, Literat O, DeGiacomo M, Kovacs A. Defective response to Toll-like receptors 3 and 4 ligands by activated monocytes in HCV infection. J Viral Hepatitis 2008; 15:137-44.
30. Palella FJ Jr, Gange SJ, Benning L, et al. Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study. AIDS 2010; 24:1657-65.
31. Clerici M, Wynn TA, Berzofsky JA, et al. Role of interleukin-10 in T helper dysfunction in asymptomatic individuals infected with the human immunodeficiency virus. J Clin Invest 1994; 93:768-75. (Pubitemid 24072820)
32. Barkan SE, Melnick SL, Preston-Martin S, et al. The Women's Interagency HIV Study. Epidemiology 1998; 9:117-25. (Pubitemid 28157608)
33. Bacon MC, von Wyl V, Alden C, et al. The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol 2005; 12:1013-9. (Pubitemid 41324530)
34. Peters L, Mocroft A, Soriano V, et al.; EuroSIDA Study Group. Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression. J Acquir Immune Defic Syndr 2009; 50:457-63.
35. Karlsson AC, Younger SR, Martin JN, et al. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. AIDS 2004; 18:981-9. (Pubitemid 38591188)
36. Weis N, Lindhardt BO, Kronborg G, et al. Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: a nationwide cohort study. Clin Infect Dis 2006; 42:1481-7.
37. Braitstein P, Zala C, Yip B, et al. Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a populationbased HIV/AIDS treatment program. J Infect Dis 2006; 193:259-68. (Pubitemid 43113488)
38. Antonucci G, Girardi E, Cozzi-Lepri A, et al. Study Group; Italian Cohort Naive for Antiretrovirals Study Group. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviralnaive HIV-infected individuals. Clin Infect Dis 2005; 40:101-9.
39. Klein MB, Lalonde RG, Suissa S. The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2003; 33:365-72. (Pubitemid 36859063)
40. Lincoln D, Petoumenos K, Dore GJ; Australian HIV Observational Database. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med 2003; 4:241-9. (Pubitemid 36949880)
41. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356:1800-5.
42. Sullivan PS, Hanson DL, Teshale EH, Wotring LL, Brooks JT. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy. AIDS 2006; 20:1171-9. (Pubitemid 43786106)
43. Rockstroh JK, Mocroft A, Soriano V, et al.; EuroSIDA Study Group. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192:992-1002. (Pubitemid 41266795)
44. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. JAMA 2002; 288: 199-206. (Pubitemid 34755280)
45. Horner SM, Gale M Jr. Intracellular innate immune cascades and interferon defenses that control hepatitis C virus. J Interferon Cytokine Res 2009; 29:489-98.
46. Kanto T, Hayashi N. Immunopathogenesis of hepatitis C virus infection: multifaceted strategies subverting innate and adaptive immunity. Intern Med 2006; 45:183-91.
47. Di Mascio M, Markowitz M, Louie M, et al. Viral blip dynamics during highly active antiretroviral therapy. J Virol 2003; 77:12165-72. (Pubitemid 37339869)
48. Mavigner M, Delobel P, Cazabat M, et al. HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS One 2009; 4: e7658.
49. Havlir DV, Strain MC, Clerici M, et al. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol 2003; 77:11212-9. (Pubitemid 37204311)
50. Cohen SB, Crawley JB, Kahan MC, Feldmann M, Foxwell BM. Interleukin-10 rescues T cells from apoptotic cell death: association with an upregulation of Bcl-2. Immunology 1997; 92:1-5. (Pubitemid 27380873)